E
Aequus Pharmaceuticals Inc.
AQSZF
$0.0039
$0.000.00%
E
Sell
7/26/2024Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 7/26/2024 due to a decline in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 7/26/2024 due to a decline in the volatility index.
D
Sell
7/11/2024Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 7/11/2024 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 41.64% from -$663.1 to -$387, earnings per share increased from -$0.004 to -$0.0037, and EBIT increased 7.4% from -$489.1 to -$452.9.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 7/11/2024 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 41.64% from -$663.1 to -$387, earnings per share increased from -$0.004 to -$0.0037, and EBIT increased 7.4% from -$489.1 to -$452.9.
E
Sell
12/26/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 12/26/2023 due to a decline in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 12/26/2023 due to a decline in the total return index and volatility index.
D
Sell
12/8/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 12/8/2023 due to an increase in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 12/8/2023 due to an increase in the volatility index.
E
Sell
11/30/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 11/30/2023 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 11/30/2023 due to a decline in the volatility index and total return index.
D
Sell
11/9/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 11/9/2023 due to an increase in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 11/9/2023 due to an increase in the volatility index and total return index.
E
Sell
10/25/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 10/25/2023 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 10/25/2023 due to a decline in the volatility index and total return index.
D
Sell
10/10/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 10/10/2023 due to an increase in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 10/10/2023 due to an increase in the total return index and volatility index.
E
Sell
9/25/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 9/25/2023 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 9/25/2023 due to a decline in the volatility index and total return index.
D
Sell
9/7/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 9/7/2023 due to an increase in the growth index and volatility index. Total revenue increased 7.48% from $68.2 to $73.3, EBIT increased 5.92% from -$528.6 to -$497.3, and earnings per share increased from -$0.0041 to -$0.0039.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 9/7/2023 due to an increase in the growth index and volatility index. Total revenue increased 7.48% from $68.2 to $73.3, EBIT increased 5.92% from -$528.6 to -$497.3, and earnings per share increased from -$0.0041 to -$0.0039.
E
Sell
9/1/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 9/1/2023 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 9/1/2023 due to a decline in the volatility index and total return index.
D
Sell
8/16/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 8/16/2023 due to an increase in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 8/16/2023 due to an increase in the volatility index.
E
Sell
8/1/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 8/1/2023 due to a decline in the volatility index and growth index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 8/1/2023 due to a decline in the volatility index and growth index.
D
Sell
7/14/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 7/14/2023 due to an increase in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 7/14/2023 due to an increase in the total return index and volatility index.
E
Sell
6/29/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 6/29/2023 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 6/29/2023 due to a decline in the volatility index and total return index.
D
Sell
6/12/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 6/12/2023 due to an increase in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 6/12/2023 due to an increase in the volatility index.
E
Sell
4/20/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 4/20/2023 due to a decline in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 4/20/2023 due to a decline in the volatility index.
D
Sell
3/30/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 3/30/2023 due to an increase in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 3/30/2023 due to an increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 03/14/2023.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 03/14/2023.
D
Sell
3/8/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 3/8/2023 due to a major decline in the solvency index and volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 3/8/2023 due to a major decline in the solvency index and volatility index.
D
Sell
2/9/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from E+ on 02/09/2023.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 02/08/2023.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 02/08/2023.
D
Sell
1/24/2023Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 1/24/2023 due to a decline in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 1/24/2023 due to a decline in the volatility index.
D
Sell
1/6/2023Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 1/6/2023 due to an increase in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 1/6/2023 due to an increase in the volatility index and total return index.
D
Sell
12/22/2022Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 12/22/2022 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 12/22/2022 due to a decline in the volatility index and total return index.
D
Sell
11/30/2022Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 11/30/2022 due to an increase in the valuation index, volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 11/30/2022 due to an increase in the valuation index, volatility index and total return index.
D
Sell
11/23/2022Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 11/23/2022 due to a decline in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 11/23/2022 due to a decline in the volatility index.
D
Sell
11/8/2022Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 11/8/2022 due to an increase in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 11/8/2022 due to an increase in the volatility index and total return index.
D
Sell
10/24/2022Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 10/24/2022 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 10/24/2022 due to a decline in the volatility index and total return index.
D
Sell
10/6/2022Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 10/6/2022 due to an increase in the volatility index, total return index and valuation index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 10/6/2022 due to an increase in the volatility index, total return index and valuation index.
D
Sell
9/21/2022Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 9/21/2022 due to a decline in the volatility index and valuation index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 9/21/2022 due to a decline in the volatility index and valuation index.
D
Sell
8/31/2022Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 8/31/2022 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.0055 to -$0.0046, total revenue increased 13.78% from $238.7 to $271.6, and EBIT increased 12.49% from -$684 to -$598.6.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 8/31/2022 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.0055 to -$0.0046, total revenue increased 13.78% from $238.7 to $271.6, and EBIT increased 12.49% from -$684 to -$598.6.
D
Sell
7/5/2022Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 7/5/2022 due to a significant decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0019 to -$0.0055, total revenue declined 65% from $682 to $238.7, and EBIT declined 22.03% from -$560.5 to -$684.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 7/5/2022 due to a significant decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0019 to -$0.0055, total revenue declined 65% from $682 to $238.7, and EBIT declined 22.03% from -$560.5 to -$684.
D
Sell
5/5/2022Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index, volatility index and growth index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index, volatility index and growth index.
D
Sell
4/20/2022Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index.
D
Sell
11/9/2021Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from E+ on 11/09/2021.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index, growth index and volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index, growth index and volatility index.
D
Sell
11/12/2020Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D from D+ on 11/12/2020 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D from D+ on 11/12/2020 due to a decline in the volatility index and total return index.
D
Sell
10/27/2020Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D+ from D on 10/27/2020 due to a substantial increase in the growth index, volatility index and total return index. Operating cash flow increased 107.61% from -$89.4 to $6.8, EBIT increased 63.25% from -$304.2 to -$111.8, and earnings per share increased from -$0.0038 to -$0.002.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D+ from D on 10/27/2020 due to a substantial increase in the growth index, volatility index and total return index. Operating cash flow increased 107.61% from -$89.4 to $6.8, EBIT increased 63.25% from -$304.2 to -$111.8, and earnings per share increased from -$0.0038 to -$0.002.
D
Sell
5/1/2020Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index and total return index.
D
Sell
4/21/2020Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 4/21/2020 due to a noticeable increase in the solvency index, volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 4/21/2020 due to a noticeable increase in the solvency index, volatility index and total return index.
E
Sell
4/2/2020Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 4/2/2020 due to a decline in the volatility index, total return index and valuation index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 4/2/2020 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/18/2020Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 3/18/2020 due to an increase in the total return index, valuation index and growth index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 3/18/2020 due to an increase in the total return index, valuation index and growth index.
E
Sell
1/29/2020Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 1/29/2020 due to a decline in the growth index, volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 1/29/2020 due to a decline in the growth index, volatility index and total return index.
D
Sell
12/19/2019Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 12/19/2019 due to an increase in the volatility index, total return index and valuation index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 12/19/2019 due to an increase in the volatility index, total return index and valuation index.
E
Sell
11/29/2019Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 11/29/2019 due to a significant decline in the solvency index, total return index and growth index. Debt to equity increased from 2 to 9.2, the quick ratio declined from 4.25 to 2.66, and total revenue declined 5.45% from $297 to $280.8.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 11/29/2019 due to a significant decline in the solvency index, total return index and growth index. Debt to equity increased from 2 to 9.2, the quick ratio declined from 4.25 to 2.66, and total revenue declined 5.45% from $297 to $280.8.
D
Sell
11/30/2018Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 11/30/2018 due to an increase in the total return index, efficiency index and valuation index. Total capital increased 76.58% from $983.2 to $1.74M, and net income increased 3.43% from -$516.3 to -$498.6.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 11/30/2018 due to an increase in the total return index, efficiency index and valuation index. Total capital increased 76.58% from $983.2 to $1.74M, and net income increased 3.43% from -$516.3 to -$498.6.
E
Sell
8/28/2018Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 8/28/2018 due to a noticeable decline in the total return index, volatility index and efficiency index. Total capital declined 31.64% from $1.44M to $983.2.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 8/28/2018 due to a noticeable decline in the total return index, volatility index and efficiency index. Total capital declined 31.64% from $1.44M to $983.2.
D
Sell
6/5/2018Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 6/5/2018 due to an increase in the solvency index and efficiency index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 6/5/2018 due to an increase in the solvency index and efficiency index.
E
Sell
5/30/2018Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 5/30/2018 due to a decline in the volatility index, total return index and efficiency index. Total capital declined 17.84% from $2.24M to $1.84M.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 5/30/2018 due to a decline in the volatility index, total return index and efficiency index. Total capital declined 17.84% from $2.24M to $1.84M.
D
Sell
2/21/2018Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 2/21/2018 due to an increase in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 2/21/2018 due to an increase in the total return index and volatility index.
E
Sell
2/6/2018Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 2/6/2018 due to a decline in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 2/6/2018 due to a decline in the volatility index.
D
Sell
1/22/2018Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 1/22/2018 due to an increase in the total return index, volatility index and growth index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 1/22/2018 due to an increase in the total return index, volatility index and growth index.
E
Sell
11/30/2017Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 11/30/2017 due to a decline in the valuation index, total return index and solvency index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 11/30/2017 due to a decline in the valuation index, total return index and solvency index.
D
Sell
10/26/2017Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 10/26/2017 due to an increase in the valuation index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 10/26/2017 due to an increase in the valuation index and total return index.
E
Sell
10/3/2017Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 10/3/2017 due to a decline in the valuation index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 10/3/2017 due to a decline in the valuation index and total return index.
D
Sell
9/15/2017Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 9/15/2017 due to an increase in the volatility index, total return index and valuation index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 9/15/2017 due to an increase in the volatility index, total return index and valuation index.
E
Sell
8/31/2017Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 8/31/2017 due to a decline in the efficiency index, growth index and total return index. Total revenue declined 37.28% from $221.3 to $138.8, EBIT declined 33.83% from -$766 to -$1.03M, and net income declined 24.09% from -$765.5 to -$949.9.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 8/31/2017 due to a decline in the efficiency index, growth index and total return index. Total revenue declined 37.28% from $221.3 to $138.8, EBIT declined 33.83% from -$766 to -$1.03M, and net income declined 24.09% from -$765.5 to -$949.9.
D
Sell
5/2/2017Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 5/2/2017 due to a significant decline in the growth index, solvency index and efficiency index. The quick ratio declined from 2.24 to 0.89, total capital declined 45.82% from $1.74M to $942.3, and total revenue declined 45.61% from $230 to $125.1.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to D- from D on 5/2/2017 due to a significant decline in the growth index, solvency index and efficiency index. The quick ratio declined from 2.24 to 0.89, total capital declined 45.82% from $1.74M to $942.3, and total revenue declined 45.61% from $230 to $125.1.
D
Sell
12/1/2016Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 12/1/2016 due to a significant increase in the growth index, efficiency index and valuation index. Total capital increased 180.09% from $620.9 to $1.74M, total revenue increased 151.15% from $91.7 to $230.3, and earnings per share increased from -$0.024 to -$0.0179.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D from D- on 12/1/2016 due to a significant increase in the growth index, efficiency index and valuation index. Total capital increased 180.09% from $620.9 to $1.74M, total revenue increased 151.15% from $91.7 to $230.3, and earnings per share increased from -$0.024 to -$0.0179.
D
Sell
8/31/2016Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 8/31/2016 due to an increase in the growth index. Operating cash flow increased 72.71% from -$1.25M to -$341, and total revenue increased 8.26% from $84.7 to $91.7.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 8/31/2016 due to an increase in the growth index. Operating cash flow increased 72.71% from -$1.25M to -$341, and total revenue increased 8.26% from $84.7 to $91.7.
E
Sell
7/28/2016Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 7/28/2016 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 7/28/2016 due to a decline in the volatility index and total return index.
D
Sell
7/13/2016Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 7/13/2016 due to an increase in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E+ on 7/13/2016 due to an increase in the total return index and volatility index.
E
Sell
6/22/2016Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 6/22/2016 due to a large decline in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E+ from D- on 6/22/2016 due to a large decline in the total return index and volatility index.
D
Sell
3/1/2016Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E on 3/1/2016 due to an increase in the valuation index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to D- from E on 3/1/2016 due to an increase in the valuation index.
E
Sell
1/19/2016Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E from E+ on 1/19/2016 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E from E+ on 1/19/2016 due to a decline in the volatility index and total return index.
E
Sell
1/4/2016Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to E+ from E on 1/4/2016 due to an increase in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to E+ from E on 1/4/2016 due to an increase in the volatility index and total return index.
E
Sell
12/16/2015Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E from E+ on 12/16/2015 due to a decline in the volatility index, growth index and valuation index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E from E+ on 12/16/2015 due to a decline in the volatility index, growth index and valuation index.
E
Sell
12/1/2015Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to E+ from E on 12/1/2015 due to an increase in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to E+ from E on 12/1/2015 due to an increase in the volatility index.
E
Sell
11/27/2015Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to E from E- on 11/27/2015 due to an increase in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to E from E- on 11/27/2015 due to an increase in the volatility index.
E
Sell
10/22/2015Downgrade
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E- from E on 10/22/2015 due to a noticeable decline in the volatility index.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E- from E on 10/22/2015 due to a noticeable decline in the volatility index.
E
Sell
9/22/2015Upgraded
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to E from E- on 9/22/2015 due to a substantial increase in the total return index, volatility index and valuation index.
Aequus Pharmaceuticals Inc. (AQSZF) was upgraded to E from E- on 9/22/2015 due to a substantial increase in the total return index, volatility index and valuation index.
E
Sell
9/9/2015None
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E- from U on 09/09/2015.
Aequus Pharmaceuticals Inc. (AQSZF) was downgraded to E- from U on 09/09/2015.
OTC PK
04/01/2025 3:27PM Eastern
Quotes delayed
